All In MedTech

Device Trial Radar · NCT07681375

Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor

Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom Sensor

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

45

Actual

Start

Apr 11, 2023

Primary completion

Jan 16, 2026

Study completion Jan 15, 2027

Sponsor

Lead sponsor
DexCom, Inc.Public (DXCM)
Sponsor type
Industry
First posted
Jul 2, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the feasibility of the DexBasal Study System

Conditions

  • Type 2 Diabetes

Interventions

  • Basal insulinDrug

    daily basal insulin dose

  • Dexcom Continuous Glucose Monitoring (CGM)Device

    Dexcom Continuous Glucose Monitoring (CGM) Sensor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measurement of participant safety while using the DexBasal Study SystemTime frame: Day 10 up to 8 weeks
  2. Measurement of system recommended doseTime frame: Day 10 up to 8 weeks
  3. Frequency of Physician approval of Dexbasal Study system's daily dose recommendationTime frame: Day 10 up to 8 weeks

10 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • San Diego Family Care (SDFC)

    San Diego, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.